Results 151 to 160 of about 29,539,706 (222)

Interleukin‐1α Mediates Pancreatic Fibroblast Activation, Regulates Immune Cell Recruitment and Fibrosis in Acute and Chronic Pancreatitis

open access: yesAdvanced Science, Volume 13, Issue 64, 16 November 2026.
During pancreatitis, IL‐1α is released from necrotic acinar cells. In response to IL‐1α, pancreatic fibroblasts release chemokines and cytokines that regulate the recruitment of immune cells to the damaged organ. Furthermore, IL‐1α primes fibroblasts, resulting in increased tissue fibrosis during chronic pancreatitis.
Hala Mazloum   +13 more
wiley   +1 more source

Identifying Systemic Lupus Erythematosus From Serum Proteomic Profiles Using Machine Learning and Genetic Risk Stratification

open access: yesArthritis &Rheumatology, Volume 78, Issue 11, Page 2280-2291, November 2026.
Objective Proteome‐wide risk models for lupus remain underexplored. We developed classification models to identify lupus from serum proteomic profiles. Methods Patients with lupus and individuals with other autoimmune diseases in the UK Biobank were included.
Mehmet Hocaoǧlu   +2 more
wiley   +1 more source

Posttranslational Modification Cross‐Talk in Vascular Cells: Molecular Mechanisms and Therapeutic Implications for Atherosclerosis

open access: yesCell Biochemistry and Function, Volume 44, Issue 11, November 2026.
ABSTRACT Atherosclerosis is driven by coordinated changes in endothelial cells (ECs), macrophages, and vascular smooth muscle cells (VSMCs). Post‐translational modifications (PTMs), phosphorylation, acetylation, ubiquitination, SUMOylation, O‐GlcNAcylation, palmitoylation, ISGylation, and ADP‐ribosylation, integrate metabolic, inflammatory, and ...
Weiwei Jiang, Haiping Du
wiley   +1 more source

Anti‐Inflammatory Therapies in Coronary Artery Disease; A Systematic Review

open access: yesClinical Cardiology, Volume 49, Issue 11, November 2026.
This review explores the evidence for anti‐inflammatory medications in prevention of MACE, effects on radiographic measurements of coronary disease, and prevention of reperfusion injury when administered in the acute setting. Of particular note are the trials concerning medications targeting the NLRP3 inflammasome pathway and its downstream products ...
Louis de Courcy, Jack Moore
wiley   +1 more source

Intravenous Lipopolysaccharide Challenge in Healthy Participants Reveals Pharmacodynamic Markers in Blood and Bone Marrow for Early‐Phase Oncology Drug Development

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1301-1314, November 2026.
Demonstrating pharmacological effects in early‐phase oncology clinical trials remains challenging, largely due to the lack of robust pharmacodynamic markers. Lipopolysaccharide (LPS) is used as an immune challenge agent in healthy participants to study drugs for autoimmune conditions.
Igor Radanović   +11 more
wiley   +1 more source

Hesperidin as a Multi‐Target Phytochemical: Therapeutic Applications, Medicinal Chemistry Insights, and Advances in Synthetic Analogs

open access: yesFood Frontiers, Volume 7, Issue 6, November 2026.
This review offers a thorough examination of the therapeutic uses of hesperidin, emphasizes significant findings from structure‐activity relationship research, and addresses recent advancements in the synthesis and biological assessment of hesperidin analogs.
Mohammadsaeed Kordi   +5 more
wiley   +1 more source

Trimethylamine N‐Oxide (TMAO), Inflammation, and Cardiovascular Risk Factors in Adults With Overweight and Obesity: Impact of Fresh Watermelon Consumption in a Randomized Controlled Crossover Trial

open access: yesFood Science &Nutrition, Volume 14, Issue 11, November 2026.
In a randomized crossover trial, 32 adults with overweight or obesity consumed 330 g/day of watermelon (100 kcal) or isocaloric low‐fat cookies (LFC) for 4 weeks, separated by a 4‐week washout. Watermelon significantly reduced within‐intervention TMAO, triglycerides, LDL cholesterol, TNF‐α, and IL‐1β.
Eryn M. Bollish   +8 more
wiley   +1 more source

CRISPR Technology: From Bench to Bedside Applications

open access: yesMedComm, Volume 7, Issue 11, November 2026.
This review systematically dissects the molecular mechanisms, advantages, and limitations of core CRISPR editing platforms including base editors (Panel A) and prime editing (Panel B); summarizes pivotal clinical data across hemoglobinopathies, CAR‐T immunotherapy, muscular dystrophy, cystic fibrosis, cardiometabolic diseases, and rare monogenic ...
Xinzhi Ma, Lingyu Li, Yingli Sun
wiley   +1 more source

Neointimal Hyperplasia and Restenosis: Epidemiology, Pathophysiology, Animal Models, Clinical Features, Diagnosis, and Management

open access: yesMedComm, Volume 7, Issue 11, November 2026.
The overall graphical diagram to summarize the pathological characteristics, pathogenesis, clinical manifestation, preclinical animal models, diagnostic methods, and intervention strategies for neointimal hyperplasia. Neointimal hyperplasia results from excessive proliferation and intimal migration of vascular smooth muscle cells (VSMCs) in the ...
Kaixu Wang   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy